Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034915.xml
Download PDF
Onkologische Welt 2011; 02(03): 137-141
DOI: 10.1055/s-0038-1631257
DOI: 10.1055/s-0038-1631257
Kongressnachlese: EAU 2011
Von Standardtherapien und kontroversen Ansätzen: Translationale Forschung und multidisziplinärer Ansätze in der Uro-Onkologie
Further Information
Publication History
Publication Date:
03 February 2018 (online)
Die gemeinsame Sitzung von EORTC GU, ESUR und ESOU diskutierte im Rahmen des EAU umfassend die modernsten Standardtherapien und kontroverse Ansätze in der Uro-Onkologie.
-
Literatur
- 1 de Bobo JS. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
- 2 Wilson PG, Fuller MT. Borisy. Monastral bipolar spindles: implications for dynamic centrosome organisation. Journal of Cell Science 1997; 110: 541-464.
- 3 Paul et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery 2010; 9: 203-214.
- 4 Bray F.. et al. Estimates of cancer incidence and mortality in Europe in 1995. EJC 2002; 38: 99-166.
- 5 Lorch A.. et al. Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. ASCO. 2010; J Clin Oncol 201 (28) 15s (suppl; abstr 4513).
- 6 Reid AHM. et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-1495.
- 7 Attard G. et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
- 8 Scher HI. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 2010; 375: 1437-1446.
- 9 Heidenreich AH. et al. EAU guideline on clinically localized prostate cancer: Compliance among urologists concerning diagnosis, staging and treatment. Eur Urol Suppl 2011; 10 Abstr. #302.
- 10 Ruprecht O. et al. MRI of the prostate: Interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol. 2011 Feb 26. [Epub ahead of print].
- 11 Garely et al. 2011
- 12 Im Blickpunkt. Der 800-Millionen-Dollar-Mythos…wa skostet die Entwicklung eines Arzneimittels wirklich?. arznei-telegramm 2011; 42: 41-43.
- 13 Light DW, Warburton R. BioSocieties 2011; 6: 34-50.